Spectrum of severe ocular complications following dupilumab exposure: A perspective from the ophthalmology clinic

J Am Acad Dermatol. 2022 Aug;87(2):469-472. doi: 10.1016/j.jaad.2021.10.015. Epub 2021 Oct 20.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Interleukin-4 Receptor alpha Subunit
  • Ophthalmology*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin-4 Receptor alpha Subunit
  • dupilumab